Non-invasive Intracranial Pressure Estimation by Measurement of the Occlusion Pressure of the Isolated Periorbital Vein

NCT07222826 | Recruiting FDA Device

• 1 other identifier: NICE-ICP
• Study Type: interventional
• Target: 15
• Locations: 1 country
• Sites: 1

Brief Summary

Elevated intracranial pressure is a common complication of brain injury which means that the pressure within the skull rises above normal levels. The negative impact of increased intracranial pressure (ICP) on the prognosis of patients has been strongly shown in numerous studies and ICP-based treatment is associated with an important reduction of risk of death. Invasive ICP measurement methods are nowadays a standard of care in severe brain injury. The two available ways of measuring ICP require neurosurgical procedure to implant a catheter and probes within the brain and present risks and complications for the patient, such as infections and intracranial bleeding. In addition, invasive recording of ICP requires neurosurgical expertise and intensive care unit (ICU) facilities, limiting the application of ICP measurements to patients of the acute neuro-ICU (neuro-Intensive Care Unit) with acute brain damage requiring close surveillance to prevent further deterioration of neural tissue and disability. Non-invasive ICP monitoring benefits include no risk of complications seen in invasive monitoring, helping in deciding which patient needs invasive ICP monitoring, and providing ongoing long-term measurements of ICP without having to insert a new device every time. Although many non-invasive ICP measurement methods have been explored, to date, none of them have shown clinical success or usefulness. One under-explored window to ICP is the orbital vein, a small blood vessel located near your eye, which we think could provide a direct link to the intracranial pressure. The study device, called the CPMX3 system, is a non-invasive method to measure pressure in a superficial periorbital vein.

Conditions

Intracranial Pressure; Intracranial Pressure Changes

Outcome Measures

Primary Outcomes (4)

• Safety of venous pressure of the isolated periorbital vein measured with the CPMX3 System to estimate ICP, evaluated by incidence of reported adverse events

  up to 7 days

• Safety of venous pressure of the isolated periorbital vein measured with the CPMX3 System to estimate ICP, evaluated by incidence of reported Device Deficiencies (DDs)

  Up to 7 days

• Safety of venous pressure of the isolated periorbital vein measured with the CPMX3 System to estimate ICP, evaluated by incidence of reported Serious Adverse Device Effects (SADEs)

  Up to 7 Days

• Preliminary accuracy of venous pressure of the isolated periorbital vein measured with the CPMX3 System to estimate ICP, measured in mmHg

  Preliminary accuracy will be assessed by recording paired measurements of venous occlusion pressure of the periorbital vein when isolated from its surrounding network and invasive ICP measurements from the standard of care invasive ICP monitor in mmHg

  up to 7 days

Secondary Outcomes (2)

• Feasibility of finding and compressing the target periorbital vein as reported by the investigator using a visual analog scale 0 to 3

  up to 7 days

• The tolerability of the non-invasive measurement process, evaluated via a dedicated patient questionnaire on patient comfort

  up to 7 days

Study Arms (1)

CPMX3 Measurement

EXPERIMENTAL

CPMX 3 measurement

Device: CPMX3

Interventions

CPMX3 DEVICE

CPMX3 periorbital vein pressure measurement

CPMX3 Measurement

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female
• Age \> 18
• Equipped with an invasive ICP monitor as part of standard of care

You may not qualify if:

• Presence of facial and/or skull trauma that could hinder placement of the pneumatic mask or contraindicate ultrasound on the forehead
• History of recent cranial surgery or hemicraniectomy
• Active bleeding (proven or suspected)
• History or known pathological condition or injury linked to the orbital socket influencingvenous outflow (e.g. Grave disease, tumor, inflammation, trauma, glaucoma, etc.)
• History, or known vein stenosis in ophthalmic veins/cavernous sinus
• Any other condition that would interfere with measurement technique and routine clinical care according to the judgment of the investigator.

Sponsors & Collaborators

• Compremium AG: lead

Study Sites (1)

Baylor College of Medicine

Houston, Texas, 77030, United States

RECRUITING

Central Study Contacts

Damon Judges

CONTACT

+41775071995; d.judges@compremium.ch

Charlotte Moerman

CONTACT

c.moerman@compremium.ch

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 10, 2025
• First Posted: October 30, 2025
• Study Start: September 30, 2025
• Primary Completion (Estimated): September 30, 2026
• Study Completion (Estimated): September 30, 2026
• Last Updated: October 30, 2025

Record last verified: 2025-10

Locations

US (1)